Recombinant protein-directed palladium nanoparticles for small molecule and drug synthesis

Description:

Technology / 19-47: Recombinant protein-directed palladium nanoparticles for small molecule & drug              synthesis

Inventor:                  Imann Mosleh, Robert Beitle, Mohammad Hassan

Status:                     This invention is available for licensing

 

General Description

 

The University of Arkansas has developed a technology capable of reducing costs associated with the preparation of organic and small molecules that rely on precious inorganic catalysis. Moreover, this technology eliminates the challenge associated with property-controllable synthesis of nanoparticles with narrow size distribution.

This process has also been used to synthesize novel molecules and drug candidates.  In fact, six new molecules including an anti-breast cancer drug precursor have been developed using these recombinant protein-templated palladium nanoparticles as a catalyst.

 

Benefits

 

  • Higher Turn Over Frequency (TOF)
  • Less costly starting material. 
  • Drug synthesis with less steps.

 

Applications

 

These recombinant protein-directed palladium nanoparticles simplify and reduce the cost of Suzuki and Stille coupling reactions. The singular roadblock to widespread development and commercialization of peptide-directed nanoparticle synthesis platforms is the high cost of chemically-synthesized peptides. For example, it would be cost prohibitive to manufacture precious nanoparticles such as platinum or palladium, where the metals are valued at $200 - $2,000 per gram when the peptide costs normally exceed $10,000 per gram. Such a differential is even more exacerbating for a nonprecious nanoparticle or when the peptide length grows to incorporate multiple functional domains. 

 

Significance

 

According to MarketsandMarkets the metal nanoparticles market was valued at USD 10.92 Billion in 2016, and is projected to reach USD 25.26 Billion by 2022, at a CAGR of 15.4% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022. Pharmaceutical & healthcare, Electrical & electronics, Catalyst, Personal care & cosmetics), and Region - Global Forecast to 2022 

__________________________________________

For interested parties seeking further information, feel free to contact:

Mark Allen Lanoue

Technology Manager / Tech Ventures

University of Arkansas

(479) 575-7243

malanoue@uark.edu

 

Patent Information:
For Information, Contact:
Mark Lanoue
Technology Manager
University of Arkansas
479-575-7243
malanoue@uark.edu
Inventors:
Imann Mosleh
Robert Beitle
Mohammad Hassan Beyzavi
Keywords:
© 2020. All Rights Reserved. Powered by Inteum